VXRT - Vaxart, Inc. Stock Price and Quote

VXRT [NASD]

Index	-	P/E	-	EPS (ttm)	-0.83	Insider Own	0.60%	Shs Outstand	131.61M	Perf Week	0.80%
Market Cap	101.76M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	2.35%	Shs Float	130.15M	Perf Month	-2.30%
Income	-104.60M	PEG	-	EPS next Q	-0.19	Inst Own	39.50%	Short Float / Ratio	16.62% / 13.46	Perf Quarter	-2.74%
Sales	0.20M	P/S	508.81	EPS this Y	-45.50%	Inst Trans	13.44%	Short Interest	21.63M	Perf Half Y	-67.52%
Book/sh	0.84	P/B	0.90	EPS next Y	-19.30%	ROA	-60.60%	Target Price	6.12	Perf Year	-85.53%
Cash/sh	0.71	P/C	1.06	EPS next 5Y	-	ROE	-79.50%	52W Range	0.70 - 5.32	Perf YTD	-21.25%
Dividend	-	P/FCF	-	EPS past 5Y	60.80%	ROI	-97.40%	52W High	-85.78%	Beta	0.82
Dividend %	-	Quick Ratio	5.50	Sales past 5Y	-55.10%	Gross Margin	-	52W Low	8.10%	ATR	0.06
Employees	164	Current Ratio	5.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	43.22	Volatility	6.24% 7.42%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-9.80%	Profit Margin	-	Rel Volume	0.60	Prev Close	0.80
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 15 AMC	Payout	-	Avg Volume	1.61M	Price	0.76
Recom	2.00	SMA20	-3.22%	SMA50	-16.80%	SMA200	-62.96%	Volume	996,003	Change	-5.47%

Dec-29-21

Resumed

Jefferies

Buy

$13 → $12

Nov-02-21

Initiated

Cantor Fitzgerald

Overweight

$15

Jun-29-21

Downgrade

B. Riley Securities

Buy → Neutral

$13 → $9

Jun-24-21

Initiated

Jefferies

Buy

$13

Jun-11-21

Initiated

Piper Sandler

Overweight

$18

Aug-12-20

Reiterated

H.C. Wainwright

Buy

$7 → $17

Jul-13-20

Initiated

B. Riley FBR

Buy

$22

Mar-29-23 08:00AM	Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6 GlobeNewswire +6.70%
Mar-18-23 02:56AM	Vaxart, Inc. (NASDAQ:VXRT) Q4 2022 Earnings Call Transcript Insider Monkey
Mar-17-23 08:00AM	Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus GlobeNewswire
Mar-15-23 04:01PM	Vaxart Provides Business Update and Full Year 2022 Financial Results GlobeNewswire
Mar-08-23 04:05PM	Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15 GlobeNewswire
08:00AM	Loading…
Feb-14-23 08:00AM	Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate GlobeNewswire
Jan-18-23 09:00AM	Covid Isnt Going Away. New Drugs Are Coming. Barrons.com
Jan-09-23 08:27AM	Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains? Zacks
Dec-19-22 08:00AM	Vaxart Names Phillip Lee as Chief Financial Officer GlobeNewswire -14.51%
Dec-01-22 08:00AM	Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers GlobeNewswire
Nov-22-22 08:30AM	Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29 GlobeNewswire
Nov-11-22 05:47AM	Vaxart Third Quarter 2022 Earnings: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021) Simply Wall St. +7.10%
Nov-08-22 05:45PM	VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM	Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results GlobeNewswire
Nov-01-22 10:01AM	VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
05:06AM	Loading…
Oct-25-22 05:06AM	3 Supercharged Growth Stocks With 257% to 379% Upside, According to Wall Street Motley Fool +5.59%
Oct-20-22 08:30AM	Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8 GlobeNewswire
Oct-10-22 08:00AM	Vaxart to Present at World Vaccine Congress Europe 2022 on October 13 GlobeNewswire -5.70%
Oct-04-22 06:20AM	2 Struggling Stocks to Avoid Right Now Motley Fool
Sep-07-22 08:30AM	Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference GlobeNewswire
Sep-01-22 06:30AM	Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate GlobeNewswire
Aug-31-22 04:30PM	Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial GlobeNewswire
08:30AM	Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer GlobeNewswire
Aug-25-22 04:05PM	Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors GlobeNewswire -5.35%
Aug-08-22 05:35PM	VAXART, INC. (VXRT) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM	Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results GlobeNewswire
08:00AM	Vaxart Appoints W. Mark Watson to its Board of Directors GlobeNewswire
Aug-05-22 08:00AM	Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4 GlobeNewswire +5.12%
Aug-03-22 07:55AM	Could This Unknown Stock Beat Moderna in 2023? Motley Fool
Jul-29-22 10:56AM	Tablet Covid vaccine hopeful settles suit claiming it overhyped its prospects for success American City Business Journals
04:05PM	Loading…
Jul-28-22 04:05PM	Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8 GlobeNewswire
Jul-27-22 08:00AM	Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET GlobeNewswire
Jul-20-22 08:30AM	Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive GlobeNewswire +7.58%
Jul-14-22 08:00AM	Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022 GlobeNewswire
Jul-01-22 09:00AM	Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET GlobeNewswire +7.14%
Jun-30-22 08:00AM	Vaxart Announces Agreement with hVIVO to Develop Worlds First Human Omicron Challenge Model GlobeNewswire
Jun-29-22 06:00AM	3 Revolutionary Stocks I'd Buy Right Now Without Hesitation Motley Fool
Jun-16-22 04:05PM	Vaxart to Host Investor Q&A Webcast GlobeNewswire -7.53%
Jun-08-22 09:05AM	Vaxart Announces Adjournment of Annual Meeting of Stockholders GlobeNewswire
Jun-07-22 10:30AM	Better Buy: Novavax vs. Vaxart Motley Fool +9.04%
Jun-03-22 08:00AM	New Preclinical Data Demonstrate Two of Vaxarts COVID-19 Vaccine Candidates Protect Against Omicron GlobeNewswire
Jun-02-22 08:45AM	Stock Market Plunge: 2 Stocks to Avoid Right Now Motley Fool
08:30AM	Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults GlobeNewswire
08:00AM	Vaxart to Participate at the Jefferies Global Healthcare Conference GlobeNewswire
May-20-22 03:33PM	Vaxart Has Great News if Youre Afraid of Covid-19 And Youre a Hamster TipRanks +5.68%
May-19-22 08:30AM	Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission GlobeNewswire +11.39%
May-18-22 05:51AM	These 3 Former High-Flying Stocks Can Soar Up to 439%, According to Wall Street Motley Fool -6.51%
May-16-22 06:00AM	Can This 1 Thing Hurt Vaxart? Motley Fool -6.29%
May-13-22 04:17PM	Here's why meme stocks are hinting at another flashy rally for `junk stocks` Yahoo Finance +15.57%
May-09-22 05:46PM	Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results GlobeNewswire -11.24%
May-04-22 02:25PM	Vaccine Makers Slump as Moderna, Pfizer Leave Full-Year Guidance Intact Bloomberg
Apr-27-22 06:30AM	3 Stocks That Have Analysts Running for the Exit InvestorPlace
Apr-14-22 08:30AM	Vaxart to Present at World Vaccine Congress Washington 2022 on April 20 GlobeNewswire
06:00AM	3 Biotech Stocks That Could Help Make You a Fortune Motley Fool
Apr-07-22 05:51AM	3 of the Fastest-Growing Stocks on the Planet Through 2026 Motley Fool
Apr-06-22 05:21AM	3 COVID-19 Stocks With Monster Upside of Up to 355%, According to Wall Street Motley Fool
Mar-29-22 10:12AM	10 Best Biotech Stocks Under $5 Insider Monkey
Mar-26-22 11:15AM	Is Vaxart the Next Moderna? Motley Fool
06:55AM	3 No-Brainer Stocks to Buy Right Now for Less Than $6 Motley Fool
Mar-24-22 11:37AM	Is It Too Late to Buy Vaxart Stock? Motley Fool
Mar-09-22 06:30AM	These 19 Words From Vaxart Could Mean Trouble for Vaccine Rivals Motley Fool +8.68%
Feb-24-22 07:10PM	VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates Zacks +15.98%
04:05PM	Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
08:30AM	Vaxarts S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates GlobeNewswire
Feb-23-22 06:15AM	These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge Motley Fool -6.41%
Feb-17-22 03:02PM	Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to Decline Zacks -5.95%
Feb-16-22 10:58AM	ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B Zacks
09:54AM	Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss Zacks
Feb-15-22 05:55PM	Corcept Therapeutics (CORT) Q4 Earnings Beat Estimates Zacks +8.57%
Feb-14-22 08:00AM	Vaxart Appoints Edward Berg as Senior Vice President and General Counsel GlobeNewswire
Feb-11-22 11:23AM	Is Vaxart Stock a Buy Now? Motley Fool
Feb-09-22 01:23PM	Vaxart, Inc. (NASDAQ:VXRT): Are Analysts Optimistic? Simply Wall St. +7.11%
Feb-07-22 12:00PM	All You Need to Know About VAXART, INC. (VXRT) Rating Upgrade to Buy Zacks
Jan-29-22 06:55AM	Does Vaxart's Oral COVID Vaccine Have a Chance? Motley Fool
05:51AM	4 Under-the-Radar Stocks With 319% to 645% Upside in 2022, According to Wall Street Motley Fool
Jan-27-22 06:33AM	Could Vaxart's Vaccine Pill Help to End the Pandemic? Motley Fool -5.08%
05:36AM	4 of the Fastest-Growing Stocks on the Planet in 2022 Motley Fool
Jan-12-22 11:10AM	BioMarin CEO: There are biotech companies 'that probably should not be on the market today Yahoo Finance Video
06:15AM	Which Vaccine Stocks Will Make You a Fortune in 2022? Motley Fool
Jan-10-22 07:55AM	Is This Vaccine Stock a Buy? Motley Fool
06:00AM	Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger InvestorPlace
Jan-04-22 08:00AM	Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference GlobeNewswire
Dec-30-21 02:59PM	Why This Analyst Sees Over 80% Upside Potential for Vaxart Stock TipRanks
Dec-21-21 10:37AM	Vaxart Deserves More Respect on Wall Street for Its Promising Covid-19 Vaccine InvestorPlace -7.45%
Dec-20-21 06:23AM	2 Top Healthcare Stocks Ready for a Bull Run in 2022 Motley Fool
Dec-16-21 09:05AM	Vaxart to Test Cross-Reactivity of its COVID-19 Oral Vaccine Against Omicron Benzinga
08:00AM	Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron GlobeNewswire
Dec-15-21 06:00AM	3 Growth Stocks With More Potential Than Any Cryptocurrency Motley Fool +6.22%
Dec-14-21 05:51AM	4 Growth Stocks With 119% to 189% Upside in 2022, According to Wall Street Motley Fool
Dec-06-21 01:45PM	Why Shares of Pfizer, Ocugen, and Vaxart Are Losing Ground Today Motley Fool -8.70%
Dec-03-21 03:18PM	Jim Cramer is Bearish on These 10 Stocks Insider Monkey -5.53%
Dec-01-21 03:14PM	Oral Covid vaccine hopeful acquires 2nd manufacturing facility American City Business Journals -11.62%
08:00AM	Vaxart Announces Acquisition of Second GMP Manufacturing Facility GlobeNewswire
Nov-23-21 08:00AM	Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2021 on November 30, 2021 GlobeNewswire
Nov-21-21 06:00AM	3 Vaccine Latecomers That Could Double Your Money Motley Fool
Nov-18-21 04:02PM	Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart GlobeNewswire
Nov-16-21 08:00AM	Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases GlobeNewswire
Nov-11-21 04:01PM	Vaxart to Participate at Upcoming Conferences GlobeNewswire
Nov-05-21 06:25AM	3 COVID Pill Stocks That Might Be Game-Changers Motley Fool
Nov-04-21 05:25PM	VAXART, INC. (VXRT) Reports Q3 Loss, Lags Revenue Estimates Zacks -5.10%

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Watson W. Mark	Director	Dec 28	Buy	0.76	20,000	15,140	20,000	Dec 28 05:25 PM
Yedid Robert A.	Director	Aug 19	Option Exercise	0.94	26,240	24,774	37,355	Aug 22 06:06 PM
Ahmad Fuad	Interim CFO	Jun 22	Buy	3.22	5,000	16,100	5,000	Jun 23 04:32 PM
Tucker Sean	SVP, Chief Scientific Officer	Apr 22	Option Exercise	0.77	40,000	30,800	127,631	Apr 25 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience